---
title: "Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292678130.md"
description: "Atrium Therapeutics received FDA IND clearance for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome. The open-label study will enroll ~37 participants across two parts: Part A for safety/dose selection and Part B for expansion at the recommended dose. Site initiation is underway, with the first participant expected by end of 2026 and initial proof-of-concept data anticipated in H2 2027."
datetime: "2026-07-14T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292678130.md)
  - [en](https://longbridge.com/en/news/292678130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292678130.md)
generator: "portal-rs"
---

# Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start

**Atrium Therapeutics announced FDA clearance of its IND for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome.**

**Key Highlights:**

-   FDA cleared IND for ATR 1072, allowing initiation of the Corventis Phase 1/2 clinical trial.
-   Corventis is an open-label, multicenter Phase 1/2 study planned to enroll ~37 participants in two parts.
-   Part A will use multiple ascending dose cohorts for safety and dose selection; Part B is a single-arm expansion at the recommended dose.
-   Site initiation is underway; first participant expected by end of 2026, with initial proof-of-concept data anticipated in H2 2027.

Original SEC Filing: Atrium Therapeutics, Inc. \[ RNA \] - 8-K - Jul. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [RNA.US](https://longbridge.com/en/quote/RNA.US.md)

## Related News & Research

- [RNA: Advancing RNA therapies for rare cardiac diseases, with phase I/II data expected next year](https://longbridge.com/en/news/298330229.md)
- [Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results](https://longbridge.com/en/news/295865390.md)
- [New ATRI Research Identifies Key Telematics Performance Measures for Motor Carriers](https://longbridge.com/en/news/298491251.md)
- [Adlai Nortye wins FDA IND clearance for AN4035 ADC trial expansion to US](https://longbridge.com/en/news/298307049.md)
- [Surrozen submits FDA IND for SZN-8141 in diabetic macular edema](https://longbridge.com/en/news/298320376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**